Neurocrine Biosciences (NBIX)
Develops and commercializes neuroscience and rare-disease medicines led by INGREZZA.
$142.58
vs last close−1.38 (−0.96%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 99.19% | 100.82M shares | |
|---|---|---|---|
| 796 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 8.51% | 8.65M shares | |
| 22 holders · as of Sep 15, 2026 | |||
| Adds to | 107.70% | ||
101.65M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 107.70%; nothing is left for Other.
13F, as of Jun 30, 2026
796 holders · 100.82M shares · 151 new positions · 468 increased · 228 reduced · 73 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 13.71M | 13.49% | +326.0K | Aug 7, 2026 |
| JPMorgan Chase & Co | 6.40M | 6.29% | +956.6K | Aug 12, 2026 |
| Dodge & Cox | 5.58M | 5.49% | +123.7K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 4.97M | 4.89% | +247.7K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 4.55M | 4.47% | +33.4K | Aug 13, 2026 |
| State Street Corp | 4.39M | 4.31% | +31.1K | Aug 7, 2026 |
| AQR Capital Management LLC | 3.82M | 3.76% | −1.12M | Aug 14, 2026 |
| Renaissance Technologies LLC | 2.34M | 2.30% | −83.0K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 12.10% | 12.05M | 13G | Apr 28, 2025 |
| Dodge & Cox | 5.60% | 5.53M | 13G | May 14, 2025 |
| Vanguard Capital Management | 5.23% | 5.26M | 13G | Apr 30, 2026 |
| JPMorgan Chase & Co. | 5.20% | 5.20M | 13G | Jan 21, 2026 |
| State Street Corporation | 5.10% | 5.15M | Oct 17, 2024 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 14, 2026 | Matt Abernethyofficer: Chief Financial Officer | Sale | 2,311 | $157.20 | 42,808 |
| Sep 14, 2026 | David W. Boyerofficer: Chief Corp. Affairs Officer | Sale | 826 | $157.45 | 8,722 |
| Sep 9, 2026 | Eric Benevichofficer: Chief Commercial Officer | Sale | 2,154 | $154.61 | 64,408 |
| Jul 28, 2026 | Leslie V. Norwalkdirector | Sale | 1,250 | $182.01 | 1,588 |
| Jul 9, 2026 | Darin Lippoldtofficer: Chief Legal Officer | Sale | 10,000 | $179.60 | 54,729 |
| Jul 10, 2026 | Ingrid Delaetofficer: Chief Regulatory Officer | Sale | 4,367 | $181.02 | 16,225 |
| Jul 9, 2026 | Ingrid Delaetofficer: Chief Regulatory Officer | Sale | 8,433 | $178.72 | 16,225 |
| Jul 7, 2026 | Ingrid Delaetofficer: Chief Regulatory Officer | Sale | 3,401 | $178.57 | 16,225 |
| Jul 8, 2026 | Ingrid Delaetofficer: Chief Regulatory Officer | Sale | 2,737 | $178.54 | 16,225 |
| Jun 29, 2026 | Darin Lippoldtofficer: Chief Legal Officer | Sale · 2 lots | 9,800 | $170.16 | 54,729 |
House and Senate disclosures
Not reported.